CoChat

Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia: A Multicenter Study

HAVEL, RICHARD J., HUNNINGHAKE, DONALD B., ILLINGWORTH, D. ROGER, LEES, ROBERT S., STEIN, EVAN A., TOBERT, JONATHAN A., BACON, SANDRA R., BOLOGNESE, JAMES A., FROST, PHILIP H., LAMKIN, GLENN E., LEES, ANN M., LEON, ARTHUR S., GARDNER, KAY, JOHNSON, G., MELLIES, M. J., RHYMER, PATRICIA A., TUN, P. · 1987 · Annals of Internal Medicine
Cited by 213

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

STUDY OBJECTIVE: To evaluate the efficacy and tolerability of lovastatin under controlled conditions in heterozygous familial hypercholesterolemia. DESIGN: Randomized, double-blind, placebo-controlled, multicenter trial. SETTING: Five lipid clinics with a central laboratory and coordinating center. PATIENTS: 101 adult patients with heterozygous familial hypercholesterolemia. INTERVENTIONS: Patients were on a lipid-lowering diet throughout the study. After a 4-week placebo baseline period, patients were randomized to five equal treatment groups. Each group received a different sequence of placebo or lovastatin 5 to 40 mg twice daily or 20 to 40 mg once daily in the evening, during three consecutive 6-week periods. MEASUREMENTS AND MAIN RESULTS: The mean reductions in total plasma cholesterol and low-density lipoprotein cholesterol across the dosage ranges were 14% to 34% and 17% to 39%, respectively (p compared with zero and placebo less than 0.01). High-density lipoprotein cholesterol and apolipoproteins AI and AII rose slightly. Apolipoprotein B fell substantially at the higher dosage levels (-23% at 40 mg twice daily, p less than 0.01), indicating a reduction in the concentration of circulating low-density lipoprotein particles. Maximum response was achieved in 4 to 6 weeks. Twice-daily dosing was slightly more efficient than once-daily dosing. Of those patients receiving 40 mg twice a day, 89% had a fall in low-density lipoprotein cholesterol of at least 20%, and 61% had a fall of at least 40%. Adverse effects attributable to lovastatin were minimal, and no patient was withdrawn from the study. CONCLUSION: Lovastatin was well tolerated and effective in the treatment of familial hypercholesterolemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-107-5-609

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 213

Metadata

Authors
HAVEL, R. J., HUNNINGHAKE, D. B., ILLINGWORTH, D. R., LEES, R. S., STEIN, E. A., TOBERT, J. A., BACON, S. R., BOLOGNESE, J. A., FROST, P. H., LAMKIN, G. E., LEES, A. M., LEON, A. S., GARDNER, K., JOHNSON, G., MELLIES, M. J., RHYMER, P. A., & TUN, P.
Venue
Annals of Internal Medicine
Published
1987-11-01
Volume
107
Issue
5
Pages
609-615
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2133945578
Cited by
213
References
4
FWCI
42.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia: A Multicenter Study. https://app.cochat.ai/papers/10.7326/0003-4819-107-5-609
The paper
HAVEL, R. J., HUNNINGHAKE, D. B., ILLINGWORTH, D. R., LEES, R. S., STEIN, E. A., TOBERT, J. A., BACON, S. R., BOLOGNESE, J. A., FROST, P. H., LAMKIN, G. E., LEES, A. M., LEON, A. S., GARDNER, K., JOHNSON, G., MELLIES, M. J., RHYMER, P. A., & TUN, P. (1987). Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia: A Multicenter Study. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-107-5-609

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.